CAPVAXIVE Trademark

Trademark Overview

On Wednesday, August 3, 2022, a trademark application was filed for CAPVAXIVE with the United States Patent and Trademark Office. The USPTO has given the CAPVAXIVE trademark a serial number of 97532421. The federal status of this trademark filing is REGISTERED as of Tuesday, January 21, 2025. This trademark is owned by Merck Sharp & Dohme LLC. The CAPVAXIVE trademark is filed in the Pharmaceutical Products category with the following description:

Human vaccine preparations
capvaxive

General Information

Serial Number97532421
Word MarkCAPVAXIVE
Filing DateWednesday, August 3, 2022
Status700 - REGISTERED
Status DateTuesday, January 21, 2025
Registration Number7663467
Registration DateTuesday, January 21, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 20, 2023

Trademark Statements

Goods and ServicesHuman vaccine preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 24, 2022
Primary Code005
First Use Anywhere DateTuesday, August 20, 2024
First Use In Commerce DateTuesday, August 20, 2024

Trademark Owner History

Party NameMerck Sharp & Dohme LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressRahway, NJ 07065
Party NameMerck Sharp & Dohme LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressRahway, NJ 07065
Party NameMerck Sharp & Dohme LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressRahway, NJ 07065

Trademark Events

Event DateEvent Description
Saturday, August 6, 2022NEW APPLICATION ENTERED
Thursday, May 11, 2023ASSIGNED TO EXAMINER
Wednesday, August 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 31, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 20, 2023PUBLISHED FOR OPPOSITION
Tuesday, September 26, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, May 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 20, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 15, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 26, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 26, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 26, 2024SOU EXTENSION 1 FILED
Tuesday, September 26, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, September 26, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, January 26, 2024SOU EXTENSION 1 GRANTED
Tuesday, January 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 1, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, March 1, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, March 1, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, March 1, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, March 1, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 7, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, August 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 10, 2024USE AMENDMENT FILED
Thursday, October 10, 2024TEAS STATEMENT OF USE RECEIVED
Monday, December 23, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, December 23, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sunday, December 29, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sunday, December 29, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, August 7, 2024SOU EXTENSION 2 FILED
Wednesday, August 7, 2024SOU EXTENSION 2 GRANTED
Tuesday, January 21, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, January 21, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

capvaxive preparations vaccine human